Value through Innovation04 July 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas


The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy

- For media outside UK, US and Canada only

New vaccine against Bovine Viral Diarrhea: Boehringer Ingelheim receives European marketing authorization for Bovela®


First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim LUX-Breast 1 and LUX-Breast 3 data at San Antonio Breast Cancer Symposium (SABCS)

- For Media Outside the UK, US and Canada Only

New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers

- For Non-US/Non-UK/Non-Canadian Media

Investing in the development of innovative active ingredients: Boehringer Ingelheim opens a new technology centre in Biberach


Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

- For media outside UK, US and Canada only

Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

- For media outside UK, US and Canada

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

- For Non-US/Non-UK/Non-Canadian Media

New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim "Runs" to support vital programs in Diabetes and Stroke


New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy

- For Media In Asian Countries Only For Whom The Data Is Relevant For media outside the US, the UK & Canada only

Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva® Respimat® in asthma

- For media outside the US, the UK & Canada only

FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice

- Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries


Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments

- For Ex-US and Ex-UK Media Only

Winners of the 2014 European PRRS Research Award announced